Alnylam Pharmaceuticals Inc to Discuss Topline Results from ENVISION Phase 3 Study of Givosiran Conference Call Transcript
Excuse me, ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call. (Operator Instructions) Please be advised that this call is being taped at the company's request.
I would now like to turn the call over to the company. Please go ahead.
Good morning. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us in the room and available for Q&A are Pushkal Garg, our Chief Medical Officer; and Akin Akinc, General Manager of the Givosiran Program. For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investor page of our website, www.alnylam.com.
Now turning to today
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |